參松養(yǎng)心膠囊聯(lián)合倍他樂(lè)克治療心力衰竭伴室性期前收縮的療效觀察
發(fā)布時(shí)間:2018-08-19 11:27
【摘要】:目的:觀察參松養(yǎng)心膠囊聯(lián)合倍他樂(lè)克對(duì)輕中度的慢性心功能不全(Chronic cardiac insufficiency)伴室性期前收縮(Premature ventricular contraction)的患者的療效及臨床癥狀的改善,來(lái)評(píng)價(jià)兩藥聯(lián)合治療的療效。材料與方法:1.選擇2014年3月-2014年12月于遼寧省人民醫(yī)院心血管內(nèi)科的住院患者(n=60,男=29,女=31,年齡49-74歲。),隨機(jī)、序貫分為兩組。2.入選標(biāo)準(zhǔn):臨床診斷為輕中度慢性心功能不全伴室性期前收縮,心功能Ⅱ-Ⅲ級(jí),24小時(shí)動(dòng)態(tài)心電圖證實(shí)存在存在室性期前收縮且總數(shù)720次3.實(shí)驗(yàn)組為參松養(yǎng)心膠囊聯(lián)合倍他樂(lè)克治療組,n=30,男=14,女=16,年齡51-74歲,給予倍他樂(lè)克12.5mg-25mg/次,2次/日口服治療及參松養(yǎng)心膠囊4粒/次,3次/日口服治療,對(duì)照組為倍他樂(lè)克治療組,n=30,男=15,女=15,給予倍他樂(lè)克12.5mg-25mg次,2次/日口服治療,療程共12周。收集用藥前后24小時(shí)動(dòng)態(tài)心電圖(Holter)室性期前收縮總數(shù)及中醫(yī)癥候評(píng)分,觀察并記錄是否有不良事件發(fā)生。觀察用藥前后室早總數(shù)的增減及中醫(yī)癥候有無(wú)改善。結(jié)果:1.一般資料:兩組一般資料無(wú)統(tǒng)計(jì)學(xué)差異(P0.05)。2.兩組治療前后室早總數(shù):實(shí)驗(yàn)組及對(duì)照組用藥前后室性期前收縮總數(shù)均有所減少,治療前實(shí)驗(yàn)組室早平均數(shù)為1358.97±520.20次,用藥后室早平均數(shù)為555.97±333.29次,用藥后平均減少803.00±497.70次。用藥前對(duì)照組室早總數(shù)平均為1493.20±576.13次,用藥后室早總數(shù)平均為1143.27±790.66次,用藥后平均減少350.07±381.37次。從室性期前收縮減少數(shù)及減少率來(lái)看實(shí)驗(yàn)組均優(yōu)于對(duì)照組。3.中醫(yī)癥候評(píng)分:實(shí)驗(yàn)組及對(duì)照組用藥前后中醫(yī)癥候評(píng)分較前均有所降低,其中實(shí)驗(yàn)組用藥前平均評(píng)分為24.8±11.89,用藥后為7.6±7.07。對(duì)照組用藥前平均評(píng)分為26.8±12.94,用藥后為19.9±17.35。4.實(shí)驗(yàn)過(guò)程中未見(jiàn)明顯的藥物不良反應(yīng)。結(jié)論:1.參松養(yǎng)心膠囊聯(lián)合倍他樂(lè)克治療可有效降低慢性心功能不全伴室性期前收縮患者的室性期前收縮總數(shù)。2.參松養(yǎng)心膠囊聯(lián)合倍他樂(lè)克治療能有效改善心慌、胸悶、乏力、失眠、五心煩熱等中醫(yī)癥候。3.參松養(yǎng)心膠囊聯(lián)合倍他樂(lè)克治療慢性心功能不全患者伴室性期前收縮時(shí),治療效果優(yōu)于單純應(yīng)用倍他樂(lè)克進(jìn)行治療。4.未發(fā)生明顯的藥物不良反應(yīng),臨床應(yīng)用較為安全。
[Abstract]:Objective: to observe the curative effect and clinical symptom improvement of Shensong Yangxin capsule combined with Betaloc in patients with mild and moderate chronic cardiac insufficiency (Chronic cardiac insufficiency) with ventricular presystolic (Premature ventricular contraction) (VAP). Materials and methods: 1. .), patients aged 49-74 years from March 2014 to December 2014 in Department of Cardiovascular Medicine of Liaoning Provincial people's Hospital (NX 60, male 29, female 31, age 49-74) were randomly divided into two groups. Inclusion criteria: mild to moderate chronic cardiac insufficiency with ventricular extrasystole was clinically diagnosed. Cardiac function 鈪,
本文編號(hào):2191521
[Abstract]:Objective: to observe the curative effect and clinical symptom improvement of Shensong Yangxin capsule combined with Betaloc in patients with mild and moderate chronic cardiac insufficiency (Chronic cardiac insufficiency) with ventricular presystolic (Premature ventricular contraction) (VAP). Materials and methods: 1. .), patients aged 49-74 years from March 2014 to December 2014 in Department of Cardiovascular Medicine of Liaoning Provincial people's Hospital (NX 60, male 29, female 31, age 49-74) were randomly divided into two groups. Inclusion criteria: mild to moderate chronic cardiac insufficiency with ventricular extrasystole was clinically diagnosed. Cardiac function 鈪,
本文編號(hào):2191521
本文鏈接:http://www.lk138.cn/yixuelunwen/xxg/2191521.html
最近更新
教材專(zhuān)著